---
layout: default
title: Milrinone
description: "Milrinone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 106
evidence_level: L1
indication_count: 10
---

# Milrinone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Milrinone è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Milrinone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Milrinone æ˜¯ä¸€ç¨®ç£·é…¸äºŒé…¯é…¶æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°ç¦¿é«®ç—‡åŠé ­ç—›éšœç¤™æœ‰æ½›åŠ›ï¼Œå…¶ä¸­é ­ç—›éšœç¤™ï¼ˆç‰¹åˆ¥æ˜¯å¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ç›¸é—œé ­ç—›ï¼‰å·²æœ‰ç—…ä¾‹å ±å‘Šæ”¯æŒå‹•è„ˆå…§ Milrinone çš„ç™‚æ•ˆã€‚
</p>

---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Milrinoneï¼ˆç±³åŠ›å¿ƒï¼‰ |
| DrugBank ID | DB00235 |
| å°ç£å•†å“å | ç±³åŠ›å¿ƒæ³¨å°„åŠ‘0.2æ¯«å…‹/æ¯«å‡ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | å……è¡€æ€§å¿ƒè¡°ç«­çš„çŸ­æœŸç™‚æ³• |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopeciaã€hypotrichosis simplex of the scalpã€congenital hypotrichosis miliaã€diffuse alopecia areataã€headache disorderã€congestive heart failureã€migraine disorderã€migraine with brainstem auraã€trigeminal autonomic cephalalgiaã€acute pulmonary heart disease |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9991ï¼ˆç¦¿é«®ç—‡ï¼‰ |
| è­‰æ“šç­‰ç´š | L3ï¼ˆè§€å¯Ÿæ€§ç ”ç©¶/ç—…ä¾‹å ±å‘Š - é ­ç—›éšœç¤™ï¼‰ |

---



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>### è—¥ç†æ©Ÿè½‰åˆ†æ</p>

<p>Milrinone æ˜¯é¸æ“‡æ€§ç£·é…¸äºŒé…¯é…¶-3ï¼ˆPDE3ï¼‰æŠ‘åˆ¶åŠ‘ï¼Œé€éå¢åŠ ç´°èƒå…§ cAMP æ¿ƒåº¦ç™¼æ®ä½œç”¨ã€‚å…¶æ©Ÿè½‰èˆ‡é æ¸¬é©æ‡‰ç—‡çš„é—œè¯ï¼š</p>

<ol>
<li><strong>ç¦¿é«®ç—‡/æ¯›é«®ç¨€ç–ç—‡</strong>ï¼ˆTxGNN Score: 0.9991ï¼‰</li>
</ol>
<ul>
<li>PDE æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ minoxidilï¼‰å·²çŸ¥å¯ä¿ƒé€²æ¯›é«®ç”Ÿé•·</li>
<li>Milrinone ä½œç‚º PDE3 æŠ‘åˆ¶åŠ‘ç†è«–ä¸Šå¯èƒ½æœ‰é¡ä¼¼ä½œç”¨</li>
<li>ä½†ç¼ºä¹ç›´æ¥è­‰æ“š</li>

</ul>
<ol>
<li><strong>é ­ç—›éšœç¤™</strong>ï¼ˆTxGNN Score: 0.9946ï¼‰</li>
</ol>
<ul>
<li>Milrinone å…·æœ‰è¡€ç®¡æ“´å¼µä½œç”¨</li>
<li>å·²æœ‰ç—…ä¾‹å ±å‘Šé¡¯ç¤ºå‹•è„ˆå…§ Milrinone å¯ç”¨æ–¼æ²»ç™‚å¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ï¼ˆRCVSï¼‰</li>
<li>é€éè§£é™¤è…¦è¡€ç®¡ç—™æ”£ä¾†ç·©è§£é ­ç—›</li>

</ul>
<ol>
<li><strong>å……è¡€æ€§å¿ƒè¡°ç«­</strong>ï¼ˆTxGNN Score: 0.9945ï¼‰</li>
</ol>
<ul>
<li>æ­¤ç‚ºåŸæ ¸å‡†é©æ‡‰ç—‡ï¼Œæœ‰è±å¯Œè‡¨åºŠè©¦é©—è­‰æ“š</li>
</ul>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>ç–¾ç—…</th>
<th>è‡¨åºŠè©¦é©—æ•¸é‡</th>
<th>æœ€é«˜æœŸåˆ¥</th>
<th>è­‰æ“šç­‰ç´š</th>
</tr>
</thead>
<tbody>
<tr>
<td>é ­ç—›éšœç¤™</td>
<td>1</td>
<td>N/Aï¼ˆè§€å¯Ÿæ€§ï¼‰</td>
<td>L3</td>
</tr>
<tr>
<td>å……è¡€æ€§å¿ƒè¡°ç«­</td>
<td>30+</td>
<td>Phase 4</td>
<td>L1</td>
</tr>
<tr>
<td>ç¦¿é«®ç—‡</td>
<td>0</td>
<td>-</td>
<td>L5</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### é ­ç—›éšœç¤™ï¼ˆå¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ï¼‰</p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>æ¨™é¡Œ</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>è­‰æ“šç­‰ç´š</th>
</tr>
</thead>
<tbody>
<tr>
<td>34784343</td>
<td>Reversible Cerebral Vasoconstriction Syndrome in Eclampsia Responding to Milrinone</td>
<td>2021</td>
<td>ç—…ä¾‹å ±å‘Š</td>
<td>L3</td>
</tr>
<tr>
<td>25440342</td>
<td>Novel approach to diagnose reversible cerebral vasoconstriction syndrome</td>
<td>2015</td>
<td>ç—…ä¾‹ç³»åˆ—</td>
<td>L3</td>
</tr>
<tr>
<td>18647181</td>
<td>Intra-arterial milrinone for reversible cerebral vasoconstriction syndrome</td>
<td>2009</td>
<td>ç—…ä¾‹å ±å‘Š</td>
<td>L3</td>
</tr>
</tbody>
</table>

<p><strong>é—œéµç™¼ç¾</strong>ï¼š</p>
<ul>
<li>å¤šç¯‡ç—…ä¾‹å ±å‘Šé¡¯ç¤ºå‹•è„ˆå…§ Milrinone å¯å¿«é€Ÿæ”¹å–„ RCVS ç›¸é—œçš„è…¦è¡€ç®¡ç—™æ”£å’Œç¥ç¶“ç—‡ç‹€</li>
<li>ç‰¹åˆ¥é©ç”¨æ–¼éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘æ²»ç™‚ç„¡æ•ˆçš„ç—…ä¾‹</li>
<li>ä½œç‚º PDE æŠ‘åˆ¶åŠ‘ï¼Œå¯æœ‰æ•ˆé¬†å¼›è¡€ç®¡å¹³æ»‘è‚Œ</li>
</ul>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. diffuse alopecia areata</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. headache disorder</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.46%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06205758" target="_blank">NCT06205758</a></td><td>N/A</td><td>UNKNOWN</td><td>1600</td><td>Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34784343/" target="_blank">34784343</a></td><td>2021</td><td>Article</td><td>The American journal</td><td>Reversible Cerebral Vasoconstriction Syndrome in a Backgroun...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25440342/" target="_blank">25440342</a></td><td>2015</td><td>Article</td><td>Journal of stroke an</td><td>A novel approach to diagnose reversible cerebral vasoconstri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18647181/" target="_blank">18647181</a></td><td>2009</td><td>Article</td><td>Headache</td><td>Intra-arterial milrinone for reversible cerebral vasoconstri...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. congestive heart failure</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.45%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01301313" target="_blank">NCT01301313</a></td><td>PHASE2</td><td>TERMINATED</td><td>116</td><td>Phase II Study to Evaluate the Efficacy and Safety of Levosimendan in Severe Acu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02098629" target="_blank">NCT02098629</a></td><td>PHASE2</td><td>COMPLETED</td><td>25</td><td>Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial In...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04369573" target="_blank">NCT04369573</a></td><td>PHASE4</td><td>TERMINATED</td><td>100</td><td>Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06522594" target="_blank">NCT06522594</a></td><td>PHASE2</td><td>RECRUITING</td><td>20</td><td>Randomized Embedded Multifactorial Adaptive Platform in ExtraCorporeal Membrane ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03071835" target="_blank">NCT03071835</a></td><td>N/A</td><td>COMPLETED</td><td>47</td><td>A Comparative Study of Subjects tHree to Thirteen Years Past thEiR fInal Follow-...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35545181/" target="_blank">35545181</a></td><td>2023</td><td>Article</td><td>Current problems in </td><td>Meta-analysis Comparing the Efficacy of Dobutamine Versus Mi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3012226/" target="_blank">3012226</a></td><td>1986</td><td>Article</td><td>The Medical clinics </td><td>Congestive heart failure.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31865433/" target="_blank">31865433</a></td><td>2020</td><td>Article</td><td>Heart and vessels</td><td>Comparing the effects of milrinone and olprinone in patients...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36122816/" target="_blank">36122816</a></td><td>2022</td><td>Article</td><td>Journal of cardiac f</td><td>Palliative Inotropes in Advanced Heart Failure: Comparing Ou...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22664586/" target="_blank">22664586</a></td><td>2012</td><td>Article</td><td>Circulation journal </td><td>Combination of Î²-blocker and milrinone for acute heart failu...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. migraine disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.45%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. migraine with brainstem aura</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.38%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. trigeminal autonomic cephalalgia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.25%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. acute pulmonary heart disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ27 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05049590" target="_blank">NCT05049590</a></td><td>PHASE3</td><td>COMPLETED</td><td>63</td><td>Acute Normovolemic Hemodilution (ANH) in Complex Cardiac Surgery</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05194514" target="_blank">NCT05194514</a></td><td>NA</td><td>COMPLETED</td><td>20</td><td>Randomized Trial to Compare the SherpaPakâ„¢ Device vs Cold Storage of Donor Heart...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04092855" target="_blank">NCT04092855</a></td><td>N/A</td><td>RECRUITING</td><td>112</td><td>Early Identification and Prediction of Right Ventricular Dysfunction and Failure...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01971944" target="_blank">NCT01971944</a></td><td>N/A</td><td>COMPLETED</td><td>50</td><td>The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope In...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04694092" target="_blank">NCT04694092</a></td><td>NA</td><td>UNKNOWN</td><td>40</td><td>Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrilla...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 22 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8659556/" target="_blank">8659556</a></td><td>1996</td><td>Article</td><td>The American journal</td><td>Milrinone: basic and clinical pharmacology and acute and chr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11096492/" target="_blank">11096492</a></td><td>1999</td><td>Article</td><td>Current treatment op</td><td>Acute Pulmonary Edema.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16582544/" target="_blank">16582544</a></td><td>2006</td><td>Article</td><td>Cardiology</td><td>Medical and ventilatory treatment of acute heart failure: ne...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16541166/" target="_blank">16541166</a></td><td>2006</td><td>Article</td><td>Tidsskrift for den N</td><td>[Medical and ventilatory treatment of acute heart failure].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21678708/" target="_blank">21678708</a></td><td>2011</td><td>Article</td><td>Prescrire internatio</td><td>Acute heart failure with dyspnoea: initial treatment. Furose...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|-----------|--------|------|-------------|------|
| ï¼ˆå¾…ç¢ºèªï¼‰ | ç±³åŠ›å¿ƒæ³¨å°„åŠ‘0.2æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ï¼ˆå¾…ç¢ºèªï¼‰ | æœ‰æ•ˆ |

**é©æ‡‰ç—‡**ï¼šå……è¡€æ€§å¿ƒè¡°ç«­çš„çŸ­æœŸç™‚æ³•ã€‚éœ€åœ¨æœ‰é©ç•¶å¿ƒé›»åœ–ç›£æ¸¬è¨­å‚™çš„ç’°å¢ƒä¸‹ä½¿ç”¨ã€‚

---

## å®‰å…¨æ€§è€ƒé‡

### ä½¿ç”¨æ³¨æ„äº‹é …

1. **å¿ƒå¾‹ä¸æ•´é¢¨éšª**
   - å¯èƒ½å¼•èµ·å±åŠç”Ÿå‘½çš„å®¤æ€§å¿ƒå¾‹ä¸æ•´
   - éœ€æŒçºŒå¿ƒé›»åœ–ç›£æ¸¬

2. **ä½¿ç”¨é™åˆ¶**
   - ç›®å‰ç„¡ä½¿ç”¨è¶…é 48 å°æ™‚çš„å°ç…§è©¦é©—ç¶“é©—
   - å»ºè­°åƒ…ä½œç‚ºçŸ­æœŸç™‚æ³•

3. **è—¥ç‰©äº¤äº’ä½œç”¨**
   - å¸¸èˆ‡ digoxin å’Œåˆ©å°¿åŠ‘ä½µç”¨
   - èˆ‡å…¶ä»–å¼·å¿ƒè—¥ç‰©ä½µç”¨æ™‚éœ€è¬¹æ…

### çµ¦è—¥é€”å¾‘è€ƒé‡

- **éœè„ˆæ³¨å°„**ï¼šå¿ƒè¡°ç«­æ¨™æº–çµ¦è—¥æ–¹å¼
- **å‹•è„ˆå…§æ³¨å°„**ï¼šRCVS æ²»ç™‚çš„ç ”ç©¶çµ¦è—¥æ–¹å¼ï¼Œéœ€å°ˆæ¥­ä»‹å…¥è¨­å‚™
- **å¸å…¥çµ¦è—¥**ï¼šè‚ºé«˜å£“æ²»ç™‚çš„ç ”ç©¶çµ¦è—¥æ–¹å¼

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè‚æ¯’æ€§ã€‚

**ä½è¡€å£“** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Thrombocytopenia** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Arrhythmias, Cardiac** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Heart Valve Diseases** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Myocardial Infarction** ğŸŸ¢ Minor
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### è©•ä¼°çµè«–

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | è‡¨åºŠè½‰è­¯å¯è¡Œæ€§ | å»ºè­°å„ªå…ˆé †åº |
|-----------|---------|---------------|-------------|
| é ­ç—›éšœç¤™ï¼ˆRCVSï¼‰ | L3 | ä¸­ç­‰ | å»ºè­°é€²ä¸€æ­¥ç ”ç©¶ |
| ç¦¿é«®ç—‡ | L5 | ä½ | ä¸å»ºè­°å„ªå…ˆé–‹ç™¼ |
| å¿ƒè¡°ç«­ | L1 | é«˜ï¼ˆå·²æ ¸å‡†ï¼‰ | ä¸é©ç”¨ |

### å»ºè­°

1. **å¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ï¼ˆRCVSï¼‰**
   - ç›®å‰å·²æœ‰å¤šç¯‡ç—…ä¾‹å ±å‘Šæ”¯æŒå‹•è„ˆå…§ Milrinone çš„ç™‚æ•ˆ
   - å»ºè­°è¨­è¨ˆå‰ç»æ€§ç ”ç©¶è©•ä¼°å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§
   - å¯è€ƒæ…®ä½œç‚ºéˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ç„¡æ•ˆæ™‚çš„æ•‘æ´æ²»ç™‚

2. **ç¦¿é«®ç—‡**
   - é›–ç„¶ PDE æŠ‘åˆ¶åŠ‘ç†è«–ä¸Šå¯èƒ½æœ‰æ•ˆ
   - ä½† Milrinone ç‚ºæ³¨å°„åŠ‘å‹ï¼Œä¸é©åˆå±€éƒ¨å¤–ç”¨æ²»ç™‚ç¦¿é«®
   - ä¸å»ºè­°é€²ä¸€æ­¥é–‹ç™¼

### å¾ŒçºŒè¡Œå‹•

- [x] ç¢ºèªé ­ç—›éšœç¤™æ–‡ç»è­‰æ“šï¼ˆå·²æœ‰ 3 ç¯‡ç—…ä¾‹å ±å‘Šï¼‰
- [ ] ç›£æ¸¬ RCVS æ²»ç™‚çš„æ–°è‡¨åºŠè©¦é©—
- [ ] è©•ä¼°æ˜¯å¦æœ‰å¯èƒ½é–‹ç™¼å±€éƒ¨å¤–ç”¨åŠ‘å‹ç”¨æ–¼ç¦¿é«®ï¼ˆå¯è¡Œæ€§ä½ï¼‰

---

*å ±å‘Šç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nitrofurantoin]({{ "/drugs/nitrofurantoin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trabectedin]({{ "/drugs/trabectedin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Zanubrutinib]({{ "/drugs/zanubrutinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Remdesivir]({{ "/drugs/remdesivir/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cladribine]({{ "/drugs/cladribine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Milrinoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/milrinone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_milrinone,
  title = {Milrinoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/milrinone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
